The estimated Net Worth of Chris Schelling is at least $3.12 Milhão dollars as of 29 November 2022. Mr Schelling owns over 819,672 units of Acer Therapeutics Inc stock worth over $2,441,276 and over the last 7 years he sold ACER stock worth over $0. In addition, he makes $675,800 as Founder, Pres, e CEO & Director at Acer Therapeutics Inc.
Mr has made over 2 trades of the Acer Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 819,672 units of ACER stock worth $1,000,000 on 29 November 2022.
The largest trade he's ever made was buying 819,672 units of Acer Therapeutics Inc stock on 29 November 2022 worth over $1,000,000. On average, Mr trades about 120,316 units every 107 days since 2017. As of 29 November 2022 he still owns at least 2,712,529 units of Acer Therapeutics Inc stock.
You can see the complete history of Mr Schelling stock trades at the bottom of the page.
Christopher Schelling is the Founder, Pres, CEO & Director at Acer Therapeutics Inc.
As the Founder, Pres, e CEO & Director of Acer Therapeutics Inc, the total compensation of Mr Schelling at Acer Therapeutics Inc is $675,800. There are no executives at Acer Therapeutics Inc getting paid more.
Mr Schelling is 45, he's been the Founder, Pres, e CEO & Director of Acer Therapeutics Inc since . There are 5 older and no younger executives at Acer Therapeutics Inc. The oldest executive at Acer Therapeutics Inc is Donald R. Joseph J.D., 67, who is the Chief Legal Officer & Sec..
Chris's mailing address filed with the SEC is C/O ACER THERAPEUTICS INC. ONE GATEWAY, CENTER SUITE 356, 300 WASHINGTON STREET, NEWTON, MA, 02458.
Over the last 7 years, insiders at Acer Therapeutics Inc have traded over $0 worth of Acer Therapeutics Inc stock and bought 2,078,411 units worth $11,295,691 . The most active insiders traders include Steve Aselage, Chris Schelling, eLife Science Ventures Vi Gm.... On average, Acer Therapeutics Inc executives and independent directors trade stock every 165 days with the average trade being worth of $170,051. The most recent stock trade was executed by Chris Schelling on 29 November 2022, trading 819,672 units of ACER stock currently worth $1,000,000.
acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica
Acer Therapeutics Inc executives and other stock owners filed with the SEC include: